JP4490668B2 - 下痢治療薬 - Google Patents
下痢治療薬 Download PDFInfo
- Publication number
- JP4490668B2 JP4490668B2 JP2003362828A JP2003362828A JP4490668B2 JP 4490668 B2 JP4490668 B2 JP 4490668B2 JP 2003362828 A JP2003362828 A JP 2003362828A JP 2003362828 A JP2003362828 A JP 2003362828A JP 4490668 B2 JP4490668 B2 JP 4490668B2
- Authority
- JP
- Japan
- Prior art keywords
- diarrhea
- therapeutic agent
- intestinal
- group
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003793 antidiarrheal agent Substances 0.000 title 1
- 206010012735 Diarrhoea Diseases 0.000 claims description 57
- 206010022678 Intestinal infections Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 11
- KINWYTAUPKOPCQ-YFKPBYRVSA-N Fudosteine Chemical group OC(=O)[C@@H](N)CSCCCO KINWYTAUPKOPCQ-YFKPBYRVSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- -1 methylene, ethylene, trimethylene, propylene, tetramethylene, pentane Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000004201 L-cysteine Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010016952 Food poisoning Diseases 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- RYACNFBWPDNHQG-ZCFIWIBFSA-N (2R)-2-amino-2-(3-hydroxypropylsulfanyl)propanoic acid Chemical compound C[C@@](C(=O)O)(N)SCCCO RYACNFBWPDNHQG-ZCFIWIBFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000607522 Aeromonas sobria Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- MWFRVMDVLYIXJF-UHFFFAOYSA-N S-2-hydroxyethyl-L-cysteine Natural products OC(=O)C(N)CSCCO MWFRVMDVLYIXJF-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 108010087845 Vibrio hemolysin Proteins 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940080435 lactose 250 mg Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000009868 osmotic diarrhea Diseases 0.000 description 1
- 208000028719 osmotic diarrheal disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
HO−A−S−CH2−CH(NH2)−COOH (I)
(式中、Aはアルキレン基を示す)
で表されるヒドロキシアルキルシステイン化合物またはその医薬上許容され得る塩を有効成分として含有する下痢治療薬である。
HO−A−S−CH2−CH(NH2)−COOH (I)
(式中、Aはアルキレン基を示す)
で表されるものである。
抗下痢作用:
(1)マウス腸管ループの作製
雄性マウス(SLCから購入したstd. ddyクリーンマウス 1群5〜6匹)にネンブタール麻酔液0.03mlを投与し、麻酔下に腹部正中線に沿って開腹し、小腸を取り出した。空腸から回腸部間の腸管約10cmを生理食塩水で洗浄した。洗浄した腸管を3〜5cm結紮し、腸管ループを作製した。この腸管ループ内に、下記の検体0.2mlを投与後、腸管をマウス体内に戻し、腹部を縫合した。
検体1: A23187 0.016nmol
検体2: A23187 0.016nmol + フドステイン 0.75mg
検体3: ASH 0.65μg
検体4: ASH 0.65μg + フドステイン 0.75mg
検体5: VMH 1.5μg
検体6: VMH 1.5μg + フドステイン 0.75mg
2時間30分後に開腹し、腸管の重量および腸管の長さを測定した。下痢活性は、腸管の重量(g)を腸管の長さ(cm)で除した値から求め、値が0.15以上を示した場合に下痢活性陽性とみなした。
細胞内カルシウム濃度上昇剤A23187単独投与群(検体1投与群;1群6匹)の上記式による下痢活性は0.18±0.02であるのに対し、A23187およびフドステイン投与群(検体2投与群;1群5匹)の下痢活性は0.12±0.02であり、フドステインはA23187の作用を有意 (p<0.05;t検定) に抑制していることが判明した。
錠 剤:
常法により、下記成分分量の錠剤1個を製造した。更に必要により、糖衣錠、フィルムコート錠とすることができる。
S−(5−ヒドロキシペンチル)−L−システイン 250mg
結晶セルロース 50mg
乳 糖 40mg
ヒドロキシプロピルセルロース 15mg
ステアリン酸マグネシウム 5mg
計 360mg
カプセル剤:
常法により、下記成分分量の顆粒を製造し、これを1号カプセル1個に充填してカプセル剤を製造した。
S−(4−ヒドロキシブチル)−L−システイン 125mg
結晶セルロース 87mg
軽質無水ケイ酸 35mg
タルク 3mg
計 250mg
顆 粒 剤:
常法により、下記成分分量の顆粒剤を製造した。
S−(3−ヒドロキシプロピル)−L−システイン 250mg
乳 糖 600mg
デンプン 135mg
ポリビニルピロリドン 15mg
計 1000mg
トローチ剤:
常法により、下記成分分量のトローチ剤を製造した。
S−(5−ヒドロキシペンチル)−L−システイン 250mg
ステアリン酸マグネシウム 20mg
ポリビニルピロリドン 50mg
白 糖 680mg
計 1000mg
散 剤:
常法により、下記成分分量の散剤を製造した。
S−(4−ヒドロキシブチル)−L−システイン 250mg
軽質無水ケイ酸 30mg
乳 糖 250mg
デンプン 70mg
計 600mg
シロップ剤:
常法により、下記成分分量のシロップ剤を製造した。
S−(5−ヒドロキシペンチル)−L−システイン 250mg
パラオキシ安息香酸エチル 1mg
白 糖 5 g
精製水をもって全量10mlとする。
坐 剤:
常法により、下記成分分量を溶融、撹拌後成型固化し、坐薬1個を製造した。
S−(3−ヒドロキシプロピル)−L−システイン 250mg
カカオ脂 1250mg
計 1500mg
注 射 剤:
常法により、下記成分分量の注射剤を製造した。
S−(5−ヒドロキシペンチル)−L−システイン 250mg
生理食塩水 1750mg
計 2000mg
Claims (5)
- 一般式
HO−A−S−CH2−CH(NH2)−COOH (I)
(式中、Aはアルキレン基を示す)
で表されるヒドロキシアルキルシステイン化合物またはその医薬上許容され得る塩を有効成分として含有する下痢治療薬。 - 腸管感染症に伴う下痢の治療に用いられる請求項第1項記載の下痢治療薬。
- 毒素産生細菌による腸管感染症に伴う下痢の治療に用いられる請求項第1項または第2項記載の下痢治療薬。
- 病原性ビブリオ科の細菌による腸管感染症に伴う下痢の治療に用いられる請求項第1項ないし第3項の何れかの項記載の下痢治療薬。
- 有効成分がフドステインである請求項第1項ないし第4項の何れかの項記載の下痢治療薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003362828A JP4490668B2 (ja) | 2003-10-23 | 2003-10-23 | 下痢治療薬 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003362828A JP4490668B2 (ja) | 2003-10-23 | 2003-10-23 | 下痢治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005126352A JP2005126352A (ja) | 2005-05-19 |
JP4490668B2 true JP4490668B2 (ja) | 2010-06-30 |
Family
ID=34642328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003362828A Expired - Lifetime JP4490668B2 (ja) | 2003-10-23 | 2003-10-23 | 下痢治療薬 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4490668B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105461603B (zh) * | 2015-12-29 | 2018-04-17 | 威海迪素制药有限公司 | 一种福多司坦的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892852A (en) * | 1972-06-15 | 1975-07-01 | Rech Pharm Scientifiques | Pharmaceutical compositions containing cysteine derivatives |
JPH023674A (ja) * | 1988-06-16 | 1990-01-09 | Ss Pharmaceut Co Ltd | ヒドロキシアルキルシステイン誘導体およびこれを含有する去痰剤 |
JPH1135459A (ja) * | 1997-07-16 | 1999-02-09 | Ss Pharmaceut Co Ltd | S−(3−ヒドロキシプロピル)−l−システインを含有する経口用製剤 |
-
2003
- 2003-10-23 JP JP2003362828A patent/JP4490668B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892852A (en) * | 1972-06-15 | 1975-07-01 | Rech Pharm Scientifiques | Pharmaceutical compositions containing cysteine derivatives |
JPH023674A (ja) * | 1988-06-16 | 1990-01-09 | Ss Pharmaceut Co Ltd | ヒドロキシアルキルシステイン誘導体およびこれを含有する去痰剤 |
JPH1135459A (ja) * | 1997-07-16 | 1999-02-09 | Ss Pharmaceut Co Ltd | S−(3−ヒドロキシプロピル)−l−システインを含有する経口用製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2005126352A (ja) | 2005-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8003118B2 (en) | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis | |
US4626536A (en) | Compositions for combatting toxaemia | |
ES2676168T3 (es) | Procedimientos para tratar enfermedades gastrointestinales | |
IE61507B1 (en) | Azithromycin and derivatives as antiprotozoal agents | |
Stein | The 4‐Quinolone Antibiotics: Past, Present, and Future | |
NO315608B1 (no) | Tiazolinsyre-derivater, anvendelse av dem og farmasöytiske preparater inneholdende dem | |
US4455305A (en) | Composition for the treatment of colitis ulcerosa, enteritis regionalis crohn (morbus crohn), chronic nonspecific colitis and diverticulitis and the use of salicylazobenzoic acid for the preparation of such compositions | |
SU1250172A3 (ru) | Способ получени 2,3-диарил-5-галоидтиофенов | |
KR20060052661A (ko) | 설사-우세형 과민성 대장 증후군의 치료제 | |
JP4490668B2 (ja) | 下痢治療薬 | |
US6740667B2 (en) | Antimicrobial agent | |
JPH06503806A (ja) | 胃腸疾病を処置するための5―ジフルオロメトキシ―2―[(3,4―ジメトキシ―2―ピリジル)メチルスルフィニル]ベンズイミダゾール及び抗ヘリコバクター剤含有医薬組成物 | |
US20140031328A1 (en) | Gallium compounds and methods of use to treat inflammatory bowel disease | |
EP0600582B1 (en) | Treatment for muscular dystrophy | |
O'Callaghan et al. | Vincristine toxicity unrelated to dose. | |
CN1334081A (zh) | 含有星形细胞功能改进剂作为活性组分的帕金森氏病治疗剂 | |
Kim et al. | Update on azithromycin and cardiac side effects | |
US6025393A (en) | Method for treatment of inflammatory intestinal diseases | |
CN114929224A (zh) | 治疗肝性脑病的新药物 | |
Curd et al. | N1-3: 4-dichlorophenyl-n5-isopropyl diguanide—a derivative of proguanil highly active in avian malaria | |
CA2566684C (en) | Pharmaceutical nitrones | |
US6251896B1 (en) | Compositions and methods for the management of Crohn's disease | |
RU2357730C1 (ru) | Композиционный состав цитопротекторного лекарственного средства 2-этил-6-метил-3-оксипиридина сукцинат | |
CN101081210A (zh) | 一种喹诺酮类抗生素的注射制剂 | |
CA2321265C (en) | Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20050401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050414 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050629 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050607 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060824 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070501 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20071102 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100316 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100402 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130409 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4490668 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140409 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |